Les cahiers de l'année gérontologique

, Volume 4, Issue 2, pp 50–55 | Cite as

Quelles thérapeutiques proposer dans la maladie de Parkinson du sujet âgé ?

Article Original / Original Article


Le traitement de la maladie de Parkinson du sujet âgé prend en compte plusieurs paramètres liés à l’âge : différences dans le profil clinique de la maladie, fréquence des comorbidités, moins bonne tolérance aux traitements, observance diminuée. Les médicaments de base du traitement des troubles moteurs sont la levodopa, l’entacapone et la rasagiline. Au stade évolué, l’apomorphine souscutanée ou la levodopa intraduodénale peuvent être discutées. Les troubles nonmoteurs font l’objet de traitements spécifiques. Une prise en charge par kinésithérapie et orthophonie est indispensable.

Mots clés

Maladie de Parkinson Traitement Sujet âgé Levodopa Rééducation 

What are the therapeutic options for Parkinson’s disease in elderly?


Treatment of Parkinson’s disease in elderly takes into account age-related specificity including differences in the clinical expression of the disease, increased diagnosis difficulties, differences in drugs tolerance, frequent co-morbidity, and poor adherence. Basically, drugs used to treat motor disorders are levodopa, entacapone and rasagiline. In advanced-stage, subcutaneous apomorphine and intraduodenal levodopa can be discussed. Non-motor disorders require specific treatments. Rehabilitation with physiotherapy and speech therapy is mandatory.


Parkinson’s disease Treatment Elderly Levodopa Rehabilitation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muangpaisan W, Mathews A, Hori H, Seidel D (2011) A systematic review of the worldwide prevalence and incidence of Parkinson’s disease. J Med Assoc Thai 94:749–755PubMedGoogle Scholar
  2. 2.
    Dowding CH, Shenton CL, Salek SS (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721PubMedCrossRefGoogle Scholar
  3. 3.
    Chen JJ (2010) Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 16 Suppl Implications:S87–S93Google Scholar
  4. 4.
    Kaltenboeck A, Johnson SJ, Davis MR, et al (2011) Direct costs and survival of medicare beneficiaries with early and advanced parkinson’s disease. Parkinsonism Relat Disord [Epub ahead of print]Google Scholar
  5. 5.
    Gage H, Hendricks A, Zhang S, Kazis L (2003) The relative health related quality of life of veterans with Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:163–169PubMedCrossRefGoogle Scholar
  6. 6.
    Soh SE, Morris ME, McGinley JL (2011) Determinants of healthrelated quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 17:1–9PubMedCrossRefGoogle Scholar
  7. 7.
    Conférence de consensus (2000) Maladie de Parkinson: diagnostic et traitement. Rev Neurol (Paris) 156Suppl 2 Pt 2:281–294Google Scholar
  8. 8.
    Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidencebased medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 20:523–539PubMedCrossRefGoogle Scholar
  9. 9.
    Fox SH, Katzenschlager R, Lim SY, et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26Suppl 3:S2–S41PubMedCrossRefGoogle Scholar
  10. 10.
    Seppi K, Weintraub D, Coelho M, et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26 Suppl 3:S42–S80CrossRefGoogle Scholar
  11. 11.
    Jego M, Viallet F (2009) Maladie de Parkinson du sujet âgé: prise en carge thérapeutique: médicaments à prescrire, médicaments à éviter. Rev Geriatr 34:8–11Google Scholar
  12. 12.
    Geny C (2009) Spécificités gériatriques de la maladie de Parkinson. Rev Geriatr 34:4–7Google Scholar
  13. 13.
    Petit H, Vermersch P, Pasquier F (1992) Some clinical aspects of late onset parkinsonism. Clin Neurol Neurosurg 94Suppl: S137–S138PubMedCrossRefGoogle Scholar
  14. 14.
    Diederich NJ, Moore CG, Leurgans SE, et al (2003) Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60:529–533PubMedCrossRefGoogle Scholar
  15. 15.
    Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 19:1043–1049PubMedCrossRefGoogle Scholar
  16. 16.
    Friedman A (1994) Old-onset Parkinson’s disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 89:258–261PubMedCrossRefGoogle Scholar
  17. 17.
    Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 38:1402–1406PubMedCrossRefGoogle Scholar
  18. 18.
    Bainbridge JL, Ruscin JM (2009) Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 26:145–155PubMedCrossRefGoogle Scholar
  19. 19.
    Grosset D, Antonini A, Canesi M, et al (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826–832PubMedCrossRefGoogle Scholar
  20. 20.
    Lauretani F, Maggio M, Silvestrini C, et al (2012) Parkinson’s disease (PD) in the elderly: an example of geriatric syndrome (GS)? Arch Gerontol Geriatr 54:242–246PubMedCrossRefGoogle Scholar
  21. 21.
    Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a populationbased, prospective study. J Am Geriatr Soc 48:938–942PubMedGoogle Scholar
  22. 22.
    Leopold NA, Polansky M, Hurka MR (2004) Drug adherence in Parkinson’s disease. Mov Disord 19:513–517PubMedCrossRefGoogle Scholar
  23. 23.
    Peterson AM, Takiya L, Finley R (2003) Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 60:657–665PubMedGoogle Scholar
  24. 24.
    Schlenk EA, Bernardo LM, Organist LA, et al (2008) Optimizing Medication Adherence in Older Patients: A Systematic Review. J Clin Outcomes Manag 15:595–606PubMedGoogle Scholar
  25. 25.
    Marciniak CM, Choo CM, Toledo SD, et al (2011) Do comorbidities and cognition impact functional change and discharge needs in Parkinson disease? Am J Phys Med Rehabil 90:272–280PubMedCrossRefGoogle Scholar
  26. 26.
    Goy ER, Carter JH, Ganzini L (2008) Needs and experiences of caregivers for family members dying with Parkinson disease. J Palliat Care 24:69–75PubMedGoogle Scholar
  27. 27.
    Lanoix M (2009) Palliative care and Parkinson’s disease: managing the chronic-palliative interface. Chronic Illn 5:46–55PubMedCrossRefGoogle Scholar
  28. 28.
    Lokk J (2011) Parkinson’s disease permanent care unit: managing the chronic-palliative interface. J Multidiscip Healthc 4:33–38PubMedCrossRefGoogle Scholar
  29. 29.
    Rascol O, Brooks DJ, Melamed E, et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954PubMedCrossRefGoogle Scholar
  30. 30.
    Pellicano C, Benincasa D, Giovannelli M, et al (2009) Entacapone in elderly Parkinsonian patients experiencing levodoparelated wearing-off: a pilot study. Neurol Res 31:74–76PubMedCrossRefGoogle Scholar
  31. 31.
    Goetz CG, Schwid SR, Eberly SW, et al (2006) Safety of rasagiline in elderly patients with Parkinson disease. Neurology 66:1427–1429PubMedCrossRefGoogle Scholar
  32. 32.
    Tolosa E, Stern MB (2011) Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol 19:258–264PubMedCrossRefGoogle Scholar
  33. 33.
    Chen JJ, Fernandez HH (2007) Community and long-term care management of Parkinson’s disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs Aging 24:663–680PubMedCrossRefGoogle Scholar
  34. 34.
    Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 23:1130–1136PubMedCrossRefGoogle Scholar
  35. 35.
    Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000PubMedCrossRefGoogle Scholar
  36. 36.
    Shulman LM, Minagar A, Rabinstein A, Weiner WJ (2000) The use of dopamine agonists in very elderly patients with Parkinson’s disease. Mov Disord 15:664–668PubMedCrossRefGoogle Scholar
  37. 37.
    Derost PP, Ouchchane L, Morand D, et al (2007) Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 68:1345–1355PubMedCrossRefGoogle Scholar
  38. 38.
    Vesper J, Haak S, Ostertag C, Nikkhah G (2007) Subthalamic nucleus deep brain stimulation in elderly patients—analysis of outcome and complications. BMC Neurol 7:7PubMedCrossRefGoogle Scholar
  39. 39.
    Rouaud T, Dondaine T, Drapier S, et al (2010) Pallidal stimulation in advanced Parkinson’s patients with contraindications for subthalamic stimulation. Mov Disord 25:1839–1846PubMedCrossRefGoogle Scholar
  40. 40.
    Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al (2010) The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:704–709PubMedCrossRefGoogle Scholar
  41. 41.
    Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on healthrelated quality of life of patients with Parkinson’s disease. Mov Disord 26:399–406PubMedCrossRefGoogle Scholar
  42. 42.
    Margis R, Donis KC, Schonwald SV, Rieder CR (2010) WHOQOL-OLD assessment of quality of life in elderly patients with Parkinson’s disease: influence of sleep and depressive symptoms. Rev Bras Psiquiatr 32:125–131PubMedCrossRefGoogle Scholar
  43. 43.
    Reichmann H, Schneider C, Lohle M (2009) Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism Relat Disord 15 Suppl 3:S87–S92CrossRefGoogle Scholar
  44. 44.
    Winter Y, von Campenhausen S, Arend M, et al (2011) Healthrelated quality of life and its determinants in Parkinson’s disease: results of an Italian cohort study. Parkinsonism Relat Disord 17:265–269PubMedCrossRefGoogle Scholar
  45. 45.
    Truong DD, Bhidayasiri R, Wolters E (2008) Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 266:216–228PubMedCrossRefGoogle Scholar
  46. 46.
    Zesiewicz TA, Sullivan KL, Arnulf I, et al (2010) Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74:924–931PubMedCrossRefGoogle Scholar
  47. 47.
    O’Connor DW, Sierakowski C, Chin LF, Singh D (2010) The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry 11:788–791PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2012

Authors and Affiliations

  1. 1.Département de neurologieHôpital SalpêtrièreParis cedex 13France

Personalised recommendations